GSK plc (LON:GSK) Insider Acquires £126.72 in Stock

Key Points

• Insider Emma Walmsley purchased 9 shares of GSK stock at an average price of GBX 1,408 for a total of £126.72 on August 11th.
• GSK's stock price reached GBX 1,404.50 during trading, with a 12-month high of GBX 1,678.68 and a low of GBX 1,242.50.
• Research firms have varied outlooks on GSK, with Shore Capital maintaining a "buy" rating and others like JPMorgan Chase adjusting their price targets downward.

GSK plc (LON:GSK - Get Free Report) insider Emma Walmsley acquired 9 shares of GSK stock in a transaction that occurred on Monday, August 11th. The stock was purchased at an average cost of GBX 1,408 ($18.91) per share, for a total transaction of £126.72 ($170.21).

GSK Trading Up 0.0%

Shares of LON:GSK traded up GBX 0.50 ($0.01) during trading on Tuesday, reaching GBX 1,404.50 ($18.87). 7,157,327 shares of the company were exchanged, compared to its average volume of 13,106,199. The firm has a market capitalization of £56.99 billion, a PE ratio of 22.69, a P/E/G ratio of 1.24 and a beta of 0.31. The business's fifty day simple moving average is GBX 1,425.58 and its 200-day simple moving average is GBX 1,428.05. GSK plc has a 12-month low of GBX 1,242.50 ($16.69) and a 12-month high of GBX 1,678.68 ($22.55). The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported GBX 75.30 ($1.01) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, research analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on GSK. Shore Capital reissued a "buy" rating and issued a GBX 2,000 ($26.86) price objective on shares of GSK in a research report on Wednesday, July 30th. JPMorgan Chase & Co. reduced their price objective on shares of GSK from GBX 1,460 ($19.61) to GBX 1,400 ($18.80) and set an "underweight" rating on the stock in a research report on Monday, August 4th. Berenberg Bank reissued a "hold" rating and issued a GBX 1,600 ($21.49) price objective on shares of GSK in a research report on Friday, July 18th. Finally, Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a GBX 1,450 ($19.48) price objective on shares of GSK in a research report on Thursday, July 31st.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.